General MedicationsINTRAVENOUSStandard
TYENNE
TOCILIZUMAB-AAZG
Standard Dose
80MG/4ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview TYENNE is listed in Drugs@FDA under application 761275 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TOCILIZUMAB-AAZG Form and strength INJECTABLE;INTRAVENOUS - 80MG/4ML Sponsor FRESENIUS KABI USA Submission history Latest submission status date: 2026-01-21 00:00:00.
Structured Monograph
Clinical summary
Approval overview TYENNE is listed in Drugs@FDA under application 761275 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient TOCILIZUMAB-AAZG Form and strength INJECTABLE;INTRAVENOUS - 80MG/4ML Sponsor FRESENIUS KABI USA Submission history Latest submission status date: 2026-01-21 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.